Deerfield Management’s Protagonist Therapeutics PTGX Stock Holding History

Deerfield Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,172,943	Closed	-$40.1M	–	129
2021 Q4	$40.1M	Sell	1,172,943 -221,057	-16%	-$6.99M	0.84%	37
2021 Q3	$24.7M	Buy	1,394,000 +31,210	+2%	+$1.33M	0.48%	58
2021 Q2	$61.2M	Buy	1,362,790 +104,000	+8%	+$3.43M	1.09%	21
2021 Q1	$32.6M	Sell	1,258,790 -121,181	-9%	-$3.07M	0.69%	48
2020 Q4	$27.8M	Buy	1,379,971 +200,000	+17%	+$4.3M	0.55%	59
2020 Q3	$23.1M	Buy	1,179,971 +166,476	+16%	+$3.12M	0.56%	61
2020 Q2	$17.9M	Buy	+1,013,495	New	+$12.7M	0.52%	61
2018 Q1	–	Sell	-225,000	Closed	-$4.68M	–	124
2017 Q4	$4.68M	Buy	+225,000	New	+$3.99M	0.18%	83

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Deerfield Management's PTGX Position: Q1 2022 in Review

Deerfield Management sold out of Protagonist Therapeutics (PTGX) in Q1 2022, closing a stake of 1,172,943 shares — an estimated $40.1M sold.

Deerfield Management first reported a position in PTGX in Q4 2017 and held it in 8 quarters. The position peaked at $61.2M in Q2 2021. 141 funds tracked by Wall St. Rank hold PTGX as of Q1 2022.

Deerfield Management reported no remaining Protagonist Therapeutics position as of Q1 2022 after selling out during the quarter.
Deerfield Management sold 1,172,943 Protagonist Therapeutics shares in Q1 2022, an estimated $40.1M.
Deerfield Management first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 8 quarters.
Deerfield Management's Protagonist Therapeutics position peaked at $61.2M in Q2 2021.
141 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2022.

Based on Deerfield Management's 13F filing for Q1 2022, filed 16 May 2022.